Detalhe da pesquisa
1.
Obesity and multiple myeloma: Emerging mechanisms and perspectives.
Semin Cancer Biol
; 92: 45-60, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37030643
2.
Genetic justification of COVID-19 patient outcomes using DERGA, a novel data ensemble refinement greedy algorithm.
J Cell Mol Med
; 28(4): e18105, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38339761
3.
Thrombotic and bleeding complications in patients with AL amyloidosis.
Br J Haematol
; 204(5): 1816-1824, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38321638
4.
Small RNA-seq and clinical evaluation of tRNA-derived fragments in multiple myeloma: Loss of mitochondrial i-tRFHisGTG results in patients' poor treatment outcome.
Br J Haematol
; 204(5): 1790-1800, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38414235
5.
Early microvascular coronary endothelial dysfunction precedes pembrolizumab-induced cardiotoxicity. Preventive role of high dose of atorvastatin.
Basic Res Cardiol
; 2024 Mar 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38520533
6.
How I treat relapsed multiple myeloma.
Blood
; 139(19): 2904-2917, 2022 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35007326
7.
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma.
Haematologica
; 2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38385280
8.
Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Part 1 results of a phase I/II study.
Haematologica
; 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38356458
9.
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
Ann Hematol
; 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38438627
10.
COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches.
Cell Commun Signal
; 22(1): 126, 2024 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38360719
11.
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA.
Am J Hematol
; 99(3): 396-407, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38298023
12.
INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice.
Future Oncol
; 20(14): 935-950, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38197267
13.
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
Lancet Oncol
; 24(6): e255-e269, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37269857
14.
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group.
Lancet Oncol
; 24(7): e293-e311, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414019
15.
Early prediction of COVID-19 outcome using artificial intelligence techniques and only five laboratory indices.
Clin Immunol
; 246: 109218, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36586431
16.
Outcomes of patients with light chain (AL) amyloidosis after failure of daratumumab-based therapy.
Br J Haematol
; 203(3): 411-415, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37580907
17.
miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma.
J Transl Med
; 21(1): 245, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37024879
18.
Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques.
PLoS Pathog
; 17(9): e1009701, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34551020
19.
Prognostic impact of translocation t(11;14) and of other cytogenetic abnormalities in patients with AL amyloidosis in the era of contemporary therapies.
Eur J Haematol
; 111(2): 271-278, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37218632
20.
Population pharmacokinetics and exposure-response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma.
Br J Clin Pharmacol
; 89(5): 1640-1655, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36484341